Sagimet Biosciences Inc. (SGMT:NASDAQ) closed at $9.08 on November 20, 2026, down 5.61% on the day. The stock trades 20.7% below its 52-week high of $11.45 and 101.8% above its 52-week low of $4.50. Over the past year, it gained 36.1%. Sagimet Biosciences Inc. is part of the Health Care sector.
In 252 trading sessions since November 20, 2025, SGMT closed higher on 115 days (46%). Its best day was April 27, 2026 (+38.57%) and its worst was September 24, 2026 (-12.57%). The stock moved 10% or more in a single session 13 times. It opened at least 5% above the previous day's high 4 times.
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Find more stocks like SGMT with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.